KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $583.2 million.

  • Royalty Pharma's Shares Outstanding (Weighted Average) fell 1.73% to $583.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $583.2 million, marking a year-over-year decrease of 1.73%. This contributed to the annual value of $589.2 million for FY2024, which is 1.38% down from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Shares Outstanding (Weighted Average) is $583.2 million, which was up 3.72% from $562.2 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Shares Outstanding (Weighted Average) ranged from a high of $607.2 million in Q1 2023 and a low of $562.2 million during Q2 2025.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $591.6 million, with a median of $597.4 million in 2023.
  • Per our database at Business Quant, Royalty Pharma's Shares Outstanding (Weighted Average) rose by 1.97% in 2021 and then fell by 5.89% in 2025.
  • Quarterly analysis of 5 years shows Royalty Pharma's Shares Outstanding (Weighted Average) stood at $607.2 million in 2021, then grew by 0.01% to $607.2 million in 2022, then dropped by 1.61% to $597.4 million in 2023, then fell by 1.38% to $589.2 million in 2024, then declined by 1.73% to $583.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $583.2 million for Q3 2025, versus $562.2 million for Q2 2025 and $576.5 million for Q1 2025.